Kuznicki Law is investigating the proposed sale of Seagen Inc. (NasdaqGS: SGEN) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Seagen will receive $229 in cash for each share of Seagen that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Seagen Inc. (NasdaqGS: SGEN) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.